Hu et al. demonstrated that Bortezomib, an FDA-approved small molecule for the treatment of myeloma, inhibits the expression of MMP-13, leading to a reduction of collagen type 2 degradation [82]. The gene discussed is MMP13; the disease is plasma cell myeloma.